Personalis, Inc.

Personalis, Inc., founded in 2011, is making significant strides in the Biotechnology and Health Care industries with its focus on ultrasensitive ctDNA testing. Based in Fremont, California, the company is at the forefront of transforming cancer management through personalized testing. By combining tumor-and-normal profiling with proprietary algorithms, Personalis offers advanced assays that detect minimal residual disease (MRD) and recurrences at their earliest possible stages. This aids in selecting targeted therapies and enhancing biomarker strategies essential for drug development.

The firm's ability to guide cancer care from tissue biopsy throughout a patient's journey positions it uniquely in the oncology landscape. The most recent funding round, a substantial $150.10M post-IPO equity investment dated January 27, 2021, underscores investor confidence in its technological potential and market impact. Personalis is well-poised to continue leading innovation in ctDNA testing and bolster its role in personalized cancer care workflows.